Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Benign Prostatic Hyperplasia Market - Growth, Trends, and Forecast (2019 - 2024)

Published by Mordor Intelligence Pvt Ltd Product code 704959
Published Content info 114 Pages
Delivery time: 2-3 business days
Back to Top
Benign Prostatic Hyperplasia Market - Growth, Trends, and Forecast (2019 - 2024)
Published: May 1, 2019 Content info: 114 Pages

Market Overview

Benign prostatic hyperplasia (BPH) also known as benign prostatic hypertrophy is characterized by the unusual propagation of the prostatic cells, which causes difficulties like urinary retention and infections of the urinary tract. It is most common among the aging men population, primarily driving this market.

Benign prostatic hyperplasia (BPH) is being accepted as a growing health problem of elderly men. With the rising number of elderly males in the population, the degree of the problem is projected to rise multifold over the next few years. As per a publication in the United States Census Bureau (2018), the population of people aged 65 and above in the US would increase drastically between 2016 and 2060 period. By 2030, one in five US citizens is expected to be 65 years and older, crossing 78.0 million. The diseased population is also significantly rising in the emerging markets. The advancements in early diagnosis of the disease and geriatric population are driving the demand for the benign prostatic hyperplasia market.

Scope of the Report

As per the scope of the report, Benign Prostatic Hyperplasia is a medical condition involving enlargement of the prostate gland and is highly prevalent in males. It is a non-cancerous growth of the prostate gland originating from the uncontrolled expansion of prostate cells. The common symptoms associated with BPH include frequent urination, urine initiation difficulties, weak urinary system, and inability to empty the urinary bladder. Currently, medications are the common way to treat men with mild to moderate BPH.

Key Market Trends

Alpha-Blockers is Expected to Hold Largest Share of Global Benign Prostatic Hyperplasia Market, Over the forecast period

Alpha-blockers help in relaxing the muscle of the prostate and the bladder neck, which allow urine to flow easier. Alpha-blockers work quickly and are usually the first line of treatment for men with mild to moderate symptoms. For instance, α1 blockers are recommended in the Clinical Guidelines for BPH in Japan as first-line drug therapy for lower urinary tract symptoms (LUTS) associated with BPH. Moreover, for people with high blood pressure and BPH, alpha-blockers are ideal treatment line for both the conditions. Owing to these factors, alpha-blockers accounted for the largest market share in the global benign prostatic hyperplasia market.

North America Region Holds the Largest Market Share of Benign Prostatic Hyperplasia Market

North America dominates the market owing to the high prevalence of BPH and other associated lower urinary tract symptoms. Several studies in past one era have reported a significant percentage of men in the US, aged between 45 and 80 years suffer from some type of lower urinary tract symptoms and most have some form of BPH symptoms. In addition, several hospitals across the US, and Canada have collaboration with the non-profit organization and companies such as GlaxoSmithKline in some of the projects to raise awareness and adequate resources for the treatment of urological disorders. Also, the rising geriatric population is bolstering the growth of the market. Thus, North America is a very lucrative market for the companies contributing to a large share of this market.

Competitive Landscape

The Benign Prostatic Hyperplasia Market market consists of several major players. The companies implement certain strategic initiatives such as a merger, new product launch, acquisition and partnerships that help them in strengthening their market position.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support
Table of Contents
Product Code: 64099

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Geriatric Population
    • 4.2.2 Growing Technological Advancements in Personalized Medicines
    • 4.2.3 Rising Awareness Through Campaigns
  • 4.3 Market Restraints
    • 4.3.1 Rising Preference Towards Minimally Invasive Surgeries
    • 4.3.2 Non-adherence of Patients to Pharmacological Therapy
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Drug Type
    • 5.1.1 Alpha-Blockers
    • 5.1.2 5- Alpha-Reductase Inhibitors (5-Aris)
    • 5.1.3 Alpha-Adrenergic Blockers
    • 5.1.4 Phosphodiesterase-5 Enzyme Inhibitors
    • 5.1.5 Others
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Online Pharmacies
  • 5.3 Geography
    • 5.3.1 North America
      • US
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Allergan PLC
    • 6.1.2 Astellas Pharma Inc.
    • 6.1.3 Boehringer Ingelheim
    • 6.1.4 Eli Lilly and Company
    • 6.1.5 GlaxoSmithKline PLC
    • 6.1.6 Nymox Pharmaceutical Corporation
    • 6.1.7 Pfizer, Inc
    • 6.1.8 Sanofi
    • 6.1.9 Sophiris Bio Corp
    • 6.1.10 Teva Pharmaceutical Industries Limited


Back to Top